Company profile: AvenCell Therapeutics
1.1 - Company Overview
Company description
- Provider of switchable and allogeneic CAR-T cell therapy platforms, including a Universal Switchable CAR with soluble targeting modules for hematologic malignancies and solid tumors; a CRISPR/Cas9-based platform enabling off-the-shelf CAR-T that overcomes graft-versus-host disease and immune rejection; and therapies AVC-101 (CD123 autologous) and AVC-201 (allogeneic UniCAR) for relapsed/refractory AML.
Products and services
- Allogeneic Platform: A CRISPR/Cas9-based framework engineering off-the-shelf CAR-T therapies that overcome graft-versus-host disease and immune rejection, providing durable, effective cancer treatment
- Universal Switchable CAR: A modular platform integrating CAR-T cells with flexible soluble targeting modules (TMs) to improve safety and efficacy against hematologic malignancies and solid tumors
- AVC-201: An allogeneic cell therapy combining UniCAR technology with the Allogeneic Platform to deliver an off-the-shelf product for treating relapsed/refractory AML
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to AvenCell Therapeutics
Avant Diagnostics
HQ: United States
Website
- Description: Provider of medical diagnostic technology specializing in large panel biomarker screening.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Avant Diagnostics company profile →
VisionGate
HQ: United States
Website
- Description: Provider of an automated 3D cell imaging platform for early cancer detection and prevention.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full VisionGate company profile →
BioNovion
HQ: United States
Website
- Description: Provider of immune oncology antibody discovery and development focused on antibodies for the immune therapy of cancer; U.S.-based, founded in 2011 and acquired by Aduro BioTech in 2015.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioNovion company profile →
Ratio Therapeutics
HQ: United States
Website
- Description: Provider of clinical-phase radiopharmaceuticals for solid tumors, with the Trillium platform for pharmacokinetic modulation to improve tumor-targeted delivery, the Macropa chelator for actinium-225 conjugation, FAP-targeted therapies including a PET diagnostic, and a Granzyme B PET imaging agent to monitor immune response in cancer and inflammatory diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ratio Therapeutics company profile →
Biomea Fusion
HQ: United States
Website
- Description: Provider of precision oncology and metabolic disease therapeutics based on novel covalent small molecules, including BMF-219, an oral investigational menin inhibitor for genetically defined cancers (AML, ALL, DLBCL, MM, CLL) and type 2 diabetes by enabling beta-cell proliferation and function; BMF-500, an investigational oral FLT3 inhibitor for AML; and the FUSION System, a platform for designing covalent small molecule therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biomea Fusion company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for AvenCell Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to AvenCell Therapeutics
2.2 - Growth funds investing in similar companies to AvenCell Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for AvenCell Therapeutics
4.2 - Public trading comparable groups for AvenCell Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →